Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.24 Analyst target: $10.00 Upside: 346.43%
SeaStar Medical Holding Corporation (ICU) is a forward-looking biotechnology company dedicated to innovating treatment solutions for chronic kidney disease via its proprietary technologies designed to improve renal function and minimize invasive procedures. Operating in a dynamic market with significant unmet medical demands, SeaStar's strong commitment to clinical innovation is underpinned by an extensive R&D pipeline and strategic collaborations. As the company strives to deliver transformative advancements in renal health, it presents substantial investment opportunities for institutional investors focused on the biotechnology landscape.
See the full interactive analysis & chart →Informational only — not investment advice.